Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate
cancer. It was assumed that during the study treatment >90% of the patients would achieve and
maintain castrate levels of serum testosterone.